CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2016; 37(04): 306
DOI: 10.4103/0971-5851.195733
LETTERS TO EDITOR

Early tumor shrinkage as an “on-treatment” clinical predictor of long-term outcome in solid organ cancers

Pratishtha Banga Chaudhari
Medical Officer, NMMC - Health Department, UHP, Airoli, New Mumbai, Maharashtra, India
› Author Affiliations
Financial support and sponsorship Nil.


Publication History

Article published online:
12 July 2021

© 2016. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992;10:896-903.
  • 2 Tang Y, Bycott P, Akerborg O, Jönsson L, Negrier S, Chen C. Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: A metastatic renal cell carcinoma case study. Cancer Manag Res 2014;6:365-71.
  • 3 Giessen C, Laubender RP, Fischer von Weikersthal L, Schalhorn A, Modest DP, Stintzing S, et al. Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial. Cancer Sci 2013;104:718-24.